Publication:
Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.

No Thumbnail Available
Date
2021-05-01T00:00:00Z
Authors
Authors
Gumus, Mahmut
Chen, Chieh-I
Ivanescu, Cristina
Kilickap, Saadettin
Bondarenko, Igor
Ozguroglu, Mustafa
Gogishvili, Miranda
Turk, Haci M.
Cicin, Irfan
Harnett, James
Journal Title
Journal ISSN
Volume Title
Publisher
Research Projects
Organizational Units
Journal Issue

Metrics

Search on Google Scholar

Abstract
Description
Keywords
Citation
Gumus M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., Ozguroglu M., Gogishvili M., Turk H. M. , Cicin I., Harnett J., et al., -Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021
Page Views

0

File Downloads

0

Sustainable Development Goals